Results suggest that plasma NfL, a marker of axonal degeneration that is not specific to AD [24, 25], may nevertheless enhance clinical trial design in mild-to-moderate dementia due to AD, perhaps by identifying participants who are at risk of more rapid worsening. This evidence concerns the gene NEFL and Alzheimer disease.